MOUNTAIN VIEW, Calif., April 19, 2018 -- IRIDEX Corporation (Nasdaq:IRIX) today announced the Company will release financial results for the first quarter 2018 after the close of trading on Thursday, May 3, 2018. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 5495252. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.iridex.com. A telephone replay will also be available beginning Thursday, May 3, 2018 through Friday, May 4, 2018 by dialing (855) 859-2056 for domestic callers or (404) 537-3406 for international callers, using conference ID: 5495252.
About IRIDEX
IRIDEX Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.
Investor Relations Contact
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
[email protected]


Tesla Raises Cybertruck Prices by $5,000 in US
Nvidia Options Price in $280 Billion Earnings Swing
Yindjibarndi Appeals Fortescue Mining Compensation Ruling
Trump Buys SpaceX Shares After Record IPO
Google Expands Gemini Enterprise With AI Tools for Legal Sector
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation
Meta, U.S. States Discuss Settlement in Teen Addiction Trial
SK Hynix Shares Fall as Workers Reject Wage Deal
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14%
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny
Trump Administration Plans New Drug Pricing Deals With Biotech Firms
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 



